Objective.-Several lines of evidence suggest that estrogens influence the development of osteoarthritis (OA). The aim of this study was to explore the association of two common polymorphisms within the aromatase (CYP19A1) and estrogen receptor alpha (ESR1) genes with severe OA of the lower limbs.
INTRODUCTION
Osteoarthritis (OA) is a prevalent disorder that frequently impairs the quality of life in middle aged and elderly individuals and represents a considerable economical burden to health-care systems. Among individuals over 45 years of age, several studies have reported a prevalence of hip OA of between 7 and 27%, and of approximately 16% for knee OA (1) . Joint replacement surgery, mostly at the hip and the knee, represents a major component of the activity of orthopaedic surgery departments, with the number of operations expected to increase 6 fold by the year 2030 (2) . Therefore, a better understanding of the pathophysiology of OA is important to establish effective preventive strategies. OA is currently seen as a complex disorder resulting from the interaction between acquired and genetic factors. The heritability of OA at different sites has been estimated to be approximately 75% at the spine, 65% at the hand, 60% at the hip, and 40% at the knee, with some suggestions for a more important contribution of heredity in females than in males (3;4) . Although the damage to the cartilage is frequently emphasized in OA, there is evidence suggesting that changes to the synovium and the subchondral bone are also involved in the OA disease process (5) .
Estrogens are critical modulators of bone homeostasis, in females and in males (6) . They have also been shown to modulate chondrocyte activity and the synthesis of a variety of factors, including metalloproteinases, nitric oxide and reactive oxygen species, involved in the anabolism and catabolism of the cartilage matrix (7) (8) (9) (10) . Estrogens act through the binding to two types of specific estrogen receptors (ER), encoded by different genes:  (or ESR1) and  (or ESR2). ESR1 seems to have a more consistent role in both sexes (6) . ERs are expressed by a variety of cells in the skeleton, including stromal cells, osteoblasts and chondrocytes (11) .
ER genes have been considered as appealing candidates potentially contributing to the genetic component of OA, but conflicting results have so been reported [recently reviewed by Ryder et al. (12) ]. However, various studies suggest that estrogens may indeed influence the development of OA(13); low levels of estrogens have been associated with an increased risk of OA in some studies (14) , whilst estrogen replacement therapy may have a protective role on the development of OA, both in experimental animals and in humans (15) (16) (17) (18) . In fact, increased osteophytosis has been reported in ER knock out mice (19) . However, the protective effect of estrogens has not been demonstrated in all studies, and conflicting results have been reported in primate models of OA (20) (21) (22) .
*Manuscript
In postmenopausal women and in men, the aromatization of androgenic precursors in peripheral tissues is the main source of estrogens. The reaction is catalyzed by aromatase, the product of the CYP19A1 gene, located on chromosome 15 (15q21.1). The synthesis of estrogens by aromatase-expressing bone cells may have important effects at the skeletal tissue level, independent of the circulating levels of estrogens. In fact, we have recently shown that aromatase expression is reduced in the bone tissue of patients with severe hip OA, in comparison to patients with hip fractures (23) . Therefore, we hypothesized that allelic variants of genes influencing estrogen synthesis and/or response could influence the risk of OA. The objective of this study was to explore the association of two common polymorphisms of the aromatase and ER genes with primary OA of the lower limb.
METHODS
Subjects.-We studied 5628 individuals aged 55 years and older (2177 patients with hip OA, 971 patients with knee OA and 2382 controls) recruited at three centres in Spain (Santander, Santiago and Coruña) and one centre in the United Kingdom, Oxford (table 1) Genotyping.-DNA was extracted from the peripheral blood or buccal swabs using standard procedures. Two single nucleotide polymorphisms (SNPs) were genotyped; the rs1062033 SNP located in the 5' untranslated region (5'UTR) of the aromatase gene CYP19A1 and the rs2234693 SNP located in intron 1 of the ERα gene ESR1. rs1062033 has been shown to be associated with differences in gene transcription at CYP19A1 and with BMD in postmenopausal women (24;25) , whilst rs2234693 has been suggested to influence OA risk in some studies (26) (27) (28) . In the Santander and Oxford cohorts the SNPs were genotyped by TaqMan allelic discrimination assays (Applied Biosystems, Foster City, CA, USA), as previously described (24) . In the Santiago and Coruña cohorts they were genotyped by a single-base extension procedure, involving a multiplex PCR reaction (Qiagen Multiplex PCR, Valencia, CA, USA; oligonucleotide primer sequences and PCR conditions are available upon request) followed by single-base extension reactions performed with the SNaPshot Multiplex Kit (Applied Biosystems). In each laboratory, 5% samples were analyzed at least twice in different days to confirm the genotyping reproducibility. Twelve samples were genotyped in different laboratories to check the consistency of results with both genotyping methods.
Alleles were designated according to the human reference sequences (minus strand for the 
RESULTS

Genetic variations and osteoarthritis
In the whole study group, the genotype frequencies were similar to those reported in other Caucasian populations. The CYP19A1 SNP rs1062033 genotypes were: CC 20%, CG 48%, and GG 32%. The ESR1 SNP rs2234693 genotype frequencies were: TT 30%, TC 50%, CC 20%. There was no evidence for departure from the Hardy-Weinberg equilibrium in the control groups (p>0.1). As shown in table 3, when the genotypes at both loci were combined, in women the gradient risk was somewhat higher than with any individual genotype, particularly for knee OA, with
ORs between 1.24 and 1.61 for knee OA. In men the combined analysis did not generate more significant data than when the SNPs were analysed individually (not shown).
CYP19A1 and ESR1 expression
Gene transcription of CYP19A1 and ESR1 was studied in bone samples of 49 patients undergoing hip arthroplasty (29 men, 20 women) and the results were analyzed according to the donor's genotype. rs1062033 was associated with differences in the abundance of CYP19A1 transcript with more abundant transcript in samples from individuals bearing C alleles than in those bearing G alleles (upper panel, figure 4 ). Intriguingly, significant differences in CYP19A1 transcript abundance between individuals with different genotypes of rs2234693 were also observed (lower panel, figure 4 ). However, neither the rs2234693 genotypes nor the rs1062033 genotypes were associated with differences in the amount of ESR1 transcripts in the bone samples ( figure 5 ). suggested that studies of genetic variants modulating the synthesis or activity of biological factors may be more informative than single measurements or even short interventional studies, as they originate the so-called "Mendelian randomization" (36;37) . In this multicenter study we found that two common polymorphisms related to the estrogen pathway are associated with the risk of OA. Thus, women bearing a particular genotype at the aromatasecoding gene CYP19A1 are at an increased risk for knee OA. The effect size was relatively small and not significant in individual cohorts, but it was consistent and statistically significant in the global analysis, with an odds ratio greater than 1.2. The risk genotype was common, being present in about one third of the individuals genotyped. Therefore, it may have important consequences not only at the individual level, but also at the population level.
DISCUSSION
This risk genotype was associated with reduced CYP19A1 expression in bone samples from patients with OA, thus confirming previous results obtained in patients with fractures (38;39).
We do not have data on estrogen levels, but we speculate that individuals with genotypes several of these studies, we found that the ESR1 SNP rs2234693 was also associated with the risk of OA in women, particularly at the knee (results for hip OA did not reach the conventional 0.05 statistical significance threshold) and with hip OA in men. The polymorphism is located in intron 1 and we speculated that it might influence gene transcription. However, we found no significant differences in the abundance of ESR1 transcripts across the three ESR1 genotypes. Interestingly, ESR1 genotypes were associated with statistically significant differences in CYP19A1 transcript abundance. There is no clear explanation for this result and it obviously merits further genetic and functional investigation; a relevant observation from other studies is that ER may have ligand-independent and liganddependent effects on the expression of genes including CYP19A1 (50), suggesting a transinteraction between these two genes located in different chromosomes. Whatever the explanation might be, our results suggest that the alleles associated with lower aromatase levels are associated with an increased risk of OA. They do not prove a direct causal link between the genotypes and OA, but suggest that genotype-dependent differences in estrogen levels or action influence OA risk.
Although aromatase is critical for estrogen synthesis in both postmenopausal women and men, we observed an interaction between sex and the genotypes. Thus, whereas both rs1062033 and rs2234693 genotypes were associated with knee OA in women, in men rs1062033 genotypes were not associated with either hip or knee OA, and rs2234693 genotypes were associated with hip OA, but in an opposite direction to that observed in women. The exact mechanisms explaining the sex-related differences are unclear. They may be the consequence of differences in the relative importance of acquired factors (such as physical activity) in men and women, or reflect some sex-specific responses to changes in estrogen levels, similar to what is observed in aromatase knock-out mice and in experimental models of OA (51;52).
This multicenter study included a large number of individuals, which allowed us to increase the precision of the estimates of the genetic effects. However, it had several limitations. First, we did not systematically obtain X-rays of the control subjects. Therefore, some of them may have mild asymptomatic OA, which could bias the results towards the null effect. On the other hand, although we excluded cases with secondary OA, we had limited information about anthropometric, nutritional and other environmental factors that may influence the risk of OA.
Therefore, we could not explore possible interactions between genetic and acquired factors that can be important in OA.
In conclusion, in this multicenter study we have shown that common genetic variation of the 
